News

Date
Title
Sort By:
09/04/25
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
08/25/25
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
08/13/25
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
05/28/25
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
05/15/25
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
04/08/25
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
03/12/25
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
12/18/24
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
11/06/24
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/10/24
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit